Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP MMT 95 for Childhood Soft Tissue Tumors
NCT00002898Phase 3Completed
- Sponsor
- SIOP
- Start
- Jan 1995
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, epirubicin and etoposide in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), primitive neuroectodermal tumor (PNET) and 1 more (4 arms), sponsored by SIOP. Primary endpoints: Overall Survival at 5 years and Disease-Free Survival at 5 years. Started Jan 1995; status: completed.
02
Drugs
carboplatinepirubicinetoposide
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)primitive neuroectodermal tumor (PNET)Ewing sarcoma
Beyond the preview
Go deeper on NCT00002898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002898.